ReviewFrontiers in immunology2026
Thymic regeneration and tumor immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The thymus, as a vital immune organ in the human body, provides the essential microenvironment for the development, differentiation, and maturation of T lymphocytes. With advancing age, the thymus gradually undergoes atrophy and degeneration, primarily characterized by structural disruption of thymic epithelial cells, leading to slowed T cell development and reduced output. Experimental studies have identified multiple regenerative pathways, including IL-7, KGF, BMP4, IL-22, RANKL, regulatory T cells, FOXN1-directed approaches, and sex-steroid blockade. Recent human observational studies also associate preserved thymic health with lower disease risk and better outcomes after cancer immunotherapy. However, most regenerative interventions remain preclinical, and no thymus-directed strategy has yet been shown to improve cancer immunotherapy outcomes in a randomized clinical trial. This review summarizes mechanisms of thymic involution and injury, evaluates regenerative strategies according to evidence level, and discusses the opportunities, limitations, and safety considerations for translating thymic regeneration into cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.